Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 4/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.48 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.48 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974514 | 1.00 | PYGL (0.50) | PYGLCDK2HDAC1HDAC6LNPEP | |
| SCHEMBL5926278 | 0.94 | PYGL (0.55) | PYGLCDK2HDAC1HDAC6LNPEP | |
| SCHEMBL3979419 | 0.91 | PYGL (0.47) | PYGLCDK2HDAC1HDAC6LNPEP | |
| SCHEMBL3971232 | 0.91 | PYGL (0.47) | PYGLCDK2HDAC1HDAC6LNPEP | |
| SCHEMBL6503531 | 0.89 | PYGL (0.46) | PYGLCDK2LNPEPTACR3GAA | |
| SCHEMBL6503528 | 0.89 | PYGL (0.46) | PYGLCDK2LNPEPTACR3GAA | |
| SCHEMBL3989387 | 0.85 | CDK2 (0.54) | PYGLCDK2HDAC1HDAC6LNPEP | |
| SCHEMBL5926818 | 0.85 | CDK2 (0.54) | PYGLCDK2HDAC1HDAC6LNPEP | |
| SCHEMBL3995599 | 0.83 | PSMB5 (0.51) | PYGLCDK2HDAC1HDAC6LNPEP | |
| SCHEMBL5926681 | 0.83 | ERAP1 (0.53) | PYGLGPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | PYGL 202/4885CDK2 781/4885HDAC1 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.